Observational and epidemiologic evidence suggests that sex hormones may play a role in the etiology and course of rheumatoid arthritis (RA). First, there is the recognized female preponderance among individuals with RA. Second, such a role is suggested by the documented reduction in both incidence and disease activity in RA during pregnancy. Third, an increased risk of RA development and of disease exacerbations in the postpartum period has been reported. Fourth, nulliparity has been found to be a risk factor for RA development in some studies. Finally, both men and women with RA have been shown to have reduced testosterone concentrations, further supporting the evidence for a role for gonadal hormones in the etiology of RA.

Given the suggested role of endogenous sex hormones in RA, it is possible that exposure to preparations containing exogenous gonadal hormones, such as oral contraceptives (OC) or estrogen replacement therapy (ERT), may also influence RA development. A number of epidemiological investigations investigated whether exogenous estrogens in the form of OC have a protective effect on RA development, with conflicting results. A smaller number of studies that examined the risk of RA development in women who used postmenopausal ERT were also inconclusive. It thus remains unclear whether exposure to exogenous gonadal hormones, through either OC or ERT, decreases the risk of RA.

We investigated whether exposure to either OC or ERT is associated with the development of RA. We separately examined the relationship between use of OC and of ERT on the risk of RA in a retrospective population based matched case-control study. Case patients, including all female residents of Rochester, Minnesota, ≥ 18 years of age, who first fulfilled 1987 American College of Rheumatology criteria for RA between 1955 and 1994 (n = 445), were compared with age matched female controls from the community. Multivariable conditional logistic regression models were used to determine whether OC or ERT exposure had an effect on RA development after controlling for potential confounders. We observed an inverse association between ever-use of OC and the risk of RA, which persisted after adjusting for potential confounders in multivariate analyses (OR 0.56, 95% CI 0.34, 0.92). Earlier calendar-year of first exposure to OC was associated with lower OR for RA. We found no evidence of a significant association of ERT with RA risk (adjusted OR 1.11, 95% CI 0.69, 1.78).

Exposure to OC, but not ERT, significantly reduces the risk of development of RA. The risk of developing RA is lower when OC exposure occurred in earlier years, which suggests that the higher doses of estrogens and progestins contained in earlier OC preparations may have a stronger protective effect against developing RA. While this protective effect is strong, it only explains a small portion of the observed decrease in RA incidence over the past few decades because the proportion of Rochester women exposed to OC is quite small.
been described. This study was approved by the Mayo Clinic Institutional Review Board.

The potential of this data retrieval system for population based studies has been described. The Rochester Epidemiology Project, a diagnostic indexing and medical records-linkage system, affords access to medical records from all sources of care for community residents. Each provider uses a comprehensive medical record system, and referral, response, recall and protopathic biases. We also examined whether the reported decline in RA incidence in women might be explained by the increasing frequency of OC use in the community.

MATERIALS AND METHODS
Epidemiologic research in Rochester, Minnesota, is possible because of its relative geographical isolation from other urban centers and because nearly all medical care is delivered to local residents by a small number of providers. Each provider uses a comprehensive medical record system, whereby all data collected on an individual are assembled in one data resource. The Rochester Epidemiology Project, a diagnostic indexing and medical records-linkage system that exists at the Mayo Clinic, allows access to medical records from all sources of care for community residents. The potential of this data retrieval system for population based studies has been described. This study was approved by the Mayo Clinic Institutional Review Board.

Identification of cases and controls. As cases, we included all female members of a population based inception cohort. This cohort comprised all residents of Rochester, Minnesota, ≥ 18 years of age, who first fulfilled the 1987 American College of Rheumatology (ACR) criteria for RA between 1955 and 1994. To identify these cases, all potential cases of RA were identified by searching the computerized diagnostic index of the Rochester Epidemiology Project for any diagnosis of arthritis (including degenerative arthritis or osteoarthritis) made any time between January 1, 1955, and December 31, 1994, among Rochester residents ≥ 18 years of age. The index date assigned to each case was the first date of RA diagnosis according to the ACR criteria. To select controls, each case was individually matched to one randomly selected Rochester resident with no diagnosis of inflammatory arthritis, of the same age (± 3 yrs) and sex, and who had a similar length of enrollment (± 1 yr) in the records-linkage system. This ensured that controls had a similar duration of contact with the system prior to incidence date to that of cases, and were thus matched with the RA patients by calendar year. Controls were assigned an index date corresponding to that of their matched case.

We chose the 1:1 case:control ratio on the basis of an a priori power estimate. Given our sample size of 445 case-control pairs, and expected rates of OC and ERT use in the community, we calculated that we would have 80% power to detect a 50% reduction in risk of developing RA.

Data collection. Data were collected according to a prespecified and pretested detailed protocol. The entire (inpatient and outpatient) community medical records were reviewed for the period prior to the incidence/index date of the cases and controls, respectively, using a pretested data collection form. Confirmation of the diagnosis of RA was based on fulfillment of 4 of the 7 ACR criteria. The study team, including 3 trained nurse abstractors, the principal investigator (MFD), and coinvestigator (SEG) met weekly throughout the abstraction period to ensure accuracy and consistency in data collection, interpretation of definitions, and application of study criteria. Reliability testing was carried out at the outset of the abstraction process, and again at a point midway through the data collection, where a sample of medical records was reviewed by all abstractors to ensure good interobserver and intraobserver agreement. After data abstraction for all study subjects, we performed an extensive series of checks for data consistency, proper sequences of dates, and an evaluation of missing or incomplete data. Where necessary, medical records were reviewed again, and questions were resolved at team meetings.

OC use was defined as any medical record documentation of prescription of combined (containing both estrogen and progestin) OC in premenopausal women before the index date. ERT exposure was defined as commencement of any form of oral or transdermal ERT in a postmenopausal woman before the index date. Data on topical estrogen preparations was not collected.

Information on form, dose, and duration of OC/ERT use was collected from the medical records, as were details regarding several potential confounders. Cigarette smoking was classified as ever or never before index date. Menopausal status (pre- or postmenopausal) was determined for cases and controls at their index dates. Menopause was defined as not having had menstrual periods for 6 months before the index date in the absence of pregnancy. Surgical menopause was defined as having had either a bilateral oophorectomy or a pelvic radium treatment before the index date. Age at onset of menstruation and other reproductive variables including gravidity, parity, numbers of stillbirths and miscarriages, and age at first pregnancy were recorded. Height and weight closest to index date were also recorded to enable estimation of body mass index (BMI).

Data analysis. Univariate conditional logistic regression models were used to investigate the roles of potential confounders. These potential confounders included BMI, smoking status, marital and menopausal status at index date, nulliparity, and history of surgical menopause prior to index date (Table 1). For each case-control comparison, an odds ratio (OR) and 95% confidence interval (CI) were calculated. Any potential confounder with missing data (e.g., smoking status) was also tested using logistic
regression on unmatched pairs to verify that that elimination of matched pairs with missing data did not bias the results. For the 2 primary analyses, we defined exposure as any documentation of use of OC or ERT prior to incidence date. Similar analyses for OC or ERT exposure for at least 6 months’ duration and for current OC or ERT exposure at index date were also performed. 

The backwards stepwise selection procedure was used to define a best multivariable conditional logistic regression model of potential confounding covariates, adjusting for the influence of age. OC and ERT exposure were then added to the best model of confounders to determine whether they had an effect on RA development. Interactions between covariates and with other measures of OC/ERT use (such as total duration of therapy, time from first use to index date, date of first use, and current compared to past or never use on index date) were investigated. For each model, an estimate of the OR for each exposure and for covariates was obtained along with 95% CI for the estimate. All tests were 2-sided and a result was considered statistically significant if the p value was less than 0.05. We also examined whether the OC exposure had a different effect on RA development. OC and ERT exposure were prescribed unopposed estrogen therapy without concomitant progestins (82% cases and 78% controls). A further 23% of cases and 26% of controls were exposed to stilbestrol. Transdermal estrogen (patches) was rarely used (0 cases, 2 controls). The majority of women receiving ERT were prescribed unopposed estrogen therapy without concomitant progestins (82% cases and 78% controls).

Univariate analyses showed a statistically significant protective association between ever-use of OC and the risk of RA, where 50 cases and 70 controls were exposed to OC (OR 0.57, 95% CI 0.35, 0.91) (Table 2). Examining only women with more than 6 months of OC revealed nearly identical results. We did not observe an association between current OC use and RA development (OR 1.0, 95% CI 0.4, 2.52), but this analysis included only 10 cases and 10 controls receiving OC at index date. Earlier calendar year of first OC exposure, if exposure occurred in the first 10 years following introduction of OC, was associated with still lower OR for later RA development (Figure 3). Adjusting for age and smoking status, OC exposure remained a significant predictor of RA development in multivariable models (OR 0.56, 95% CI 0.34, 0.92). When further adjusted for ERT use in addition to these variables, the OR for OC exposure was unchanged. The protective effect of OC exposure on the development of RF positive (compared to RF negative) RA was more pronounced (OR 0.36, 95% CI 0.18, 0.72) than the effect of OC exposure on RF negative RA (OR 0.982, 95% CI 0.46, 2.10), although not quite statistically significant (p = 0.06).

A significant association between ERT exposure and RA development was not observed (OR 1.26, 95% CI 0.81,
Table 2. Univariate analyses* of oral contraceptive (OC) and estrogen replacement therapy (ERT) exposures among 445 RA patients and 445 non-RA controls.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Cases, n (%)</th>
<th>Controls, n (%)</th>
<th>Odds Ratio (95% CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>OC exposure, ever use</td>
<td>50 (11.2)</td>
<td>70 (15.7)</td>
<td>0.57 (0.35, 0.91)</td>
<td>0.02</td>
</tr>
<tr>
<td>OC exposure, &gt; 6 mo</td>
<td>46 (10.3)</td>
<td>66 (14.8)</td>
<td>0.56 (0.34, 0.91)</td>
<td>0.02</td>
</tr>
<tr>
<td>OC exposure, current at RA incidence</td>
<td>10 (2.2)</td>
<td>10 (2.2)</td>
<td>1.00 (0.40, 2.52)</td>
<td>1.00</td>
</tr>
<tr>
<td>ERT exposure, any duration</td>
<td>55 (12.4)</td>
<td>46 (10.3)</td>
<td>1.26 (0.81, 1.96)</td>
<td>0.31</td>
</tr>
<tr>
<td>ERT exposure, &gt; 6 mo</td>
<td>52 (11.7)</td>
<td>39 (8.8)</td>
<td>1.42 (0.90, 2.25)</td>
<td>0.14</td>
</tr>
<tr>
<td>ERT exposure, current at RA incidence</td>
<td>22 (4.9)</td>
<td>14 (1.67)</td>
<td>1.67 (0.81, 3.41)</td>
<td>0.16</td>
</tr>
</tbody>
</table>

* Cases and controls were matched on age and calendar year.

Figure 3. Risk of development of RA according to calendar year of first exposure to oral contraceptives.

The study found an inverse association between OC exposure and development of RA, such that women experience a 44% reduction in the risk for RA following OC exposure, after controlling for potential confounders (OR 0.56, 95% CI 0.34, 0.92). Exposure to OC in earlier calendar years, when higher doses of estrogen and progestins were used in the formulations, is associated with a further lowering of risk, such that women who received OC prior to 1970 have only one-quarter the risk of unexposed women. We did not find a similar reduction in risk for postmenopausal use of ERT.

In addition to its etiologic interest, the question addressed here is of potential public health importance as OC and ERT are now widely used in the community. Rates for OC use of up to 80% of women born since 1945 have been reported, and rates for ERT range from 12% to 32% in population surveys in the United States. The incidence of RA in the population has been reported to be decreasing in a number of ways, including a 38.6% reduction. While the proportion of Rochester women exposed to OC has increased over time, it is still quite small.
of epidemiologic studies, and this decline appears to be more marked in women than in men. To determine how much of the observed decline in RA incidence in women can be attributed to increasing use of OC, we calculated attributable risks and found that a protective effect of OC exposure on the development of RA can only explain a small portion of the dramatic decrease in RA incidence over the past few decades.

Studies examining the risk of RA following exposure to OC and ERT have yielded disparate results. In the case of studies examining OC use, 14 case-control studies and 4 cohort studies have been published (Figure 1). Our findings concur with those of 4 of these case-control studies, which found a significant protective effect for ever-use of OC, with risk ratios ranging from 0.37 to 0.6. Three further case-control studies found a suggestion of a protective effect, but did not reach statistical significance. Contrasting results are reported, however, from other case-control studies, including 2 earlier studies performed at this center. Of the 4 cohort studies examining this question, only one found a protective effect for OC use on RA development. Our findings concur with the majority of studies examining ERT and RA in not finding a protective effect.

There are a number of possible reasons for these discrepant results, many of which relate to methodological challenges and potential biases inherent in these studies. We sought to overcome most of these biases to clarify this issue.

The first of these relates to the population sampled in the various studies. We included all incident cases of RA in a geographically defined region and selected controls randomly from the population. Most previous case-control studies were hospital based and may have been affected by referral and/or incidence-prevalence bias. The subjects for the cohort studies were recruited from a contraceptive clinic in one case, general practitioners in 2 cases, and from the Nurses Health Study in the other. All the women included in these studies were married, and may not be representative of the general population.

The second possible limitation of previous studies relates to case ascertainment. Of the cohort studies, 2 relied principally on self-report of RA diagnosis, and the criteria used in the other case-control and cohort studies for RA were variable. The different composition of RA cases in older studies, compared to ours, where the 1987 ACR criteria for RA were used, may explain some of the conflicting results in these studies. For ascertainment of exposure, previous case-control studies largely relied on questionnaire or interview techniques, which can predispose to both recall and response biases. In our study, exposure information was obtained through review of each subject’s complete (inpatient and outpatient) medical history, including medical record data from all healthcare providers, avoiding these potential biases.

Two further methodological issues that may explain the conflicting results of the 5 studies that examined the question of ERT and RA relate to women who underwent surgical menopause and protopathic bias. Since women who undergo surgical menopause at an earlier age are subject to reduced endogenous estrogen exposure, and are also very likely to receive treatment with replacement hormones, a true association between ERT and RA could be masked. We examined this possibility by excluding those women with surgical menopause in a subanalysis. While the resulting odds ratio (OR 1.36, 95% CI 0.81-2.28) increased slightly, it remained statistically insignificant. Protopathic bias could occur if physicians were to prescribe ERT for menopausal women with musculoskeletal symptoms and those symptoms eventually turned out to be an early manifestation of RA rather than symptoms of menopause. If ERT were commenced during the time between onset of musculoskeletal symptoms and actual RA incidence date, RA cases would be more likely to be prescribed ERT than controls and a true association could thus be obscured. For this reason, we performed the analysis excluding all study cases with any documented musculoskeletal symptoms and their matched controls. The result was unchanged (OR 1.17, 95% CI 0.75-1.84).

Our findings concur with those of most previous case-control studies examining OC use in revealing an important and statistically significant protective effect for OC use on RA risk. However, in the case of ERT, the weight of the available evidence is against such a protective effect. There are several plausible biological reasons for these apparently conflicting findings.

It has been suggested, on the basis of laboratory evidence, that the reported immunomodulatory effects of estrogen are dose-related, where lower physiological doses have immunostimulatory effects, and high doses are immunosuppressive. This could explain our finding of a stronger protective effect in earlier years following the introduction of OC, as OC contained considerably higher doses of estrogen at that time. It would also explain the lack of protection from ERT, as most estrogen supplements used for postmenopausal replacement have less than one-sixth the potency of low dose OC.

Another possible explanation for the protective effect of OC (in contrast to ERT) is that it is not the estrogen, but rather the progestin component of the OC, that exerts the protective effect. Progesterone has been shown to have immunosuppressive effects in vivo. It has been suggested that the elevated concentration of progesterone during pregnancy is, in part, responsible for the immunosuppression necessary to prevent fetal homograft rejection. A possible protective effect afforded by progestins in OC preparations could also relate to their androgenic effects. Androgens are thought to have a number of immunosuppressive effects, and both men and women with RA have been shown to have...
lower serum levels of androgens, suggesting that androgens may protect against RA. Since the majority of women prescribed ERT in this study did not receive concomitant progestins (82% cases, 78% controls), such a protective effect of progestosterone could help explain why we found that OC preparations, all of which contain a progestin component, are protective. Our finding of even greater protection for women exposed during the initial years after introduction of OC would also support this theory, as progestin doses contained in OC preparations were at least 10-fold higher prior to 1970.

It should also be noted, when considering explanations for a protective effect of OC but not for ERT, that these are very different types of preparations with different biological effects. They are generally prescribed for very different reasons and are used at different times in life. It has been speculated that aspects of behavior associated with OC use, such as smoking, pregnancy, and recurrent genital tract infections, may confer a higher risk of RA. In this study, the protective effect of OC remained unchanged even after controlling for smoking and pregnancies.

One potential limitation of this study is that the data on OC and ERT routinely documented in medical records may be incomplete. Incomplete documentation regarding exposure can lead to bias if such documentation errors were different in cases compared to controls (better documentation in cases, for example). However, the exposures of interest were those occurring before the development of RA, and were recorded prospectively in the medical record without knowledge of subsequent disease outcome. Thus, there is no reason to believe that documentation would be differential in cases compared to controls. Ascertainment for the variables of interest was generally excellent (Table 1) and the number of missing data elements was likely too small to cause significant confounding.

Another potential study limitation was incomplete blinding of the data collection. It was not possible to keep the abstractors unaware of the case or control status of the study subjects. However, with the exception of the principal investigator (MFD), who abstracted only a minority of cases, the abstractors were not aware of the hypotheses being tested, and reliability testing revealed no differences in data collection patterns among abstractors. We did not have information regarding other possible confounding factors, such as socioeconomic status and education level, which may be important. Finally, some racial and ethnic groups are underrepresented in Rochester, MN, where the population was 96% white in 1990 (US census data). Thus, the results of our population based study are not necessarily generalizable to the entire US population.

Evidence from observational studies regarding the influence of OC and ERT on the risk of RA has been controversial. Our study, the design of which minimized many of the biases of previous case-control studies that examined this question, finds evidence for a strong protective effect of OC exposure on the development of RA. However, this effect does not appear to explain the declining incidence of RA in women. Our findings are consistent with most of the evidence regarding ERT use, which fails to find a similar protective effect. Further research, including both clinical studies and laboratory studies in the field of immunocrinology, may help to explain the complex relationship between estrogen, progestins, and RA.

ACKNOWLEDGMENT
Thanks to Denise Herman, RN, Deanne Stiebner, RN, and Patricia Hartkopf, RN for their work on data abstraction for this study, and Deborah Fogarty for assistance in the preparation of the manuscript.

REFERENCES


44. Feher KG, Feher T, Merety K. Interrelationship between the immunological and steroid hormone parameters in rheumatoid arthritis. Exp Clin Endocrinol 1986;87:38-42.
